The Coalition Against Patent Abuse (CAPA) aims to stop Big Pharma from gaming the system to extend their monopolies at consumers’ expense. At CAPA we come together with the collective acknowledgment that America’s drug spending problem cannot be addressed without examining government-granted monopolies that prevent drug price competition for decades, but which do not represent either innovation or the best interests of public health. Essentially, patent abuse and extension of regulatory monopolies not only keep drug prices high, they also slow innovation and prevent timely access to better, affordable medicines to save and enhance patients’ lives.
Big Pharma companies have enormous incentives to block market entry of lower-cost, generic drugs, for as long as possible.
For example, AbbVie Inc.’s rheumatoid arthritis drug Humira is the world’s best-selling prescription drug in the world, with over $16 billion in U.S. sales per year.
Humira was approved in 2002, and it now makes more money annually than all of the NFL teams, combined.
Other examples of Pharma’s tactics include:
Inter Partes Review (IPR) is an important tool that Congress enacted as a bi-partisan solution to allow the PTO to eliminate bad patents efficiently…
Brand name drug companies often attempt to bury competition from generic and biosimilar drugs indefinitely by finding ways to re-package existing inventions in later patents…
Product hopping is a tactic brand name drug companies use to prevent generic competition by forcing patients to switch to new formulations of a drug, with new patents, often with little or no therapeutic difference…
Filing citizen petitions with the FDA allows the public to raise concerns with the FDA and is often completely legitimate…
CAPA will work to find practical solutions to reduce patent system abuse and regulatory manipulation that blocks or delays our access to safe, lower-cost medicines. This includes working to:
Strengthen the PTO
Strengthen the policing power of the PTO, the patent system, and the courts to ensure that only true innovation is rewarded by patents and their government-granted monopolies.
Oppose Big Pharma
Oppose efforts by Big Pharma and its allies to roll back IPR and U.S. Supreme Court rulings that make it easier to eliminate invalid, non-innovative patents.
Reduce and eliminate the legal and regulatory gamesmanship and chronic, late-stage patenting that stops generic and biosimilar competition in its tracks.
Who We Are
We are building a new coalition of healthcare providers and payers, consumer groups, patient advocacy organizations, employers, and other stakeholders to fight abuses of the patent system that can extend government-granted monopolies illegitimately for years, even decades.
Sign Up for CAPA Updates.
If you wish to learn more please fill out the form below. We will send you regular updates on what we are doing and other important information.